Astera Labs stock (NASDAQ: $ALAB) has been one of the standout AI semiconductor stories of the past year, climbing from roughly $120 to around $420 a share — a gain of about 3.5x — while surviving a brutal 60% drawdown along the way. This Astera Labs stock analysis breaks down what’s actually driving the ALAB stock price, compares its financials against direct peers Marvell ($MRVL) and Credo Technology ($CRDO), and weighs whether the current valuation still makes sense.
If you’re searching for an honest answer to “is ALAB stock overvalued” or “ALAB vs MRVL vs CRDO,” this is the breakdown.
Key Takeaways
- $ALAB stock price: up from ~$120 to ~$420 in twelve months (+3.5x)
- Q1 FY26 revenue: $308.4 million, +93% year-over-year
- GAAP gross margin: 76.3% — the highest of its direct peer group
- Valuation: ~49x forward EV/EBITDA, well above the semiconductor sector average
- Analyst gap: consensus 12-month price target (~$245) sits roughly 40% below the current ALAB stock price
ALAB Stock Price History: The One-Year Journey
Astera Labs’ one-year chart doesn’t move in a straight line — and that’s the part most headlines about the “meteoric rise” leave out.
- June 2025: ~$120 already a strong post-IPO performer riding early AI infrastructure demand
- September 2025: ~$252 an all time- high close as the AI connectivity narrative accelerated
- October 2025 – January 2026: a sharp correction, with ALAB stock eventually bottoming near $104 by March 2026 on margin and valuation concerns
- April–June 2026: a sharp recovery driven by a Q1 FY26 earnings beat, Scorpio X-Series momentum, and Nasdaq-100 inclusion
- Today (June 20, 2026): trading around $420, just off a fresh all-time high, up more than 20% in the past week alone
A stock that gets cut in half and still finishes the year up 3.5x is a fundamentally different story than one that simply went straight up. The drawdown is what makes the recovery credible. Astera Labs had to re-earn investor confidence with results, not just sentiment.
What’s Driving Astera Labs Stock Right Now
Astera Labs designs semiconductor connectivity chips, the “plumbing” that lets GPUs, CPUs, and memory communicate inside AI data centers. It’s the smallest of its direct public peers by revenue, but its Q1 FY26 results (reported May 2026) explain why the ALAB stock price has re-rated so aggressively:
- Revenue: $308.4 million, up 93% year-over-year and 14% sequentially
- GAAP gross margin: 76.3% (non-GAAP: 76.4%)
- GAAP net income: $80.3 million, swinging from a net loss a year earlier
- Non-GAAP operating margin: 36.2%
- Cash and marketable securities: $1.2 billion, against total liabilities of just $165.3 million
Astera Labs carries almost no debt and holds over a billion dollars in cash — unusually strong for a semiconductor company this early in its growth curve.
Forward guidance was equally strong: $355–365 million in Q2 revenue, another double-digit sequential increase. Management did flag that Q2 non-GAAP gross margin would dip to roughly 73%, about 340 basis points below Q1 — attributed mainly to a one-time, non-cash accounting impact from a customer warrant agreement rather than underlying pricing pressure.
Two additional catalysts are fueling the ALAB stock rally:
- Scorpio X-Series — a 320-lane AI scale-up fabric switch built for frontier AI workloads, now shipping and ramping
- Nasdaq-100 inclusion, effective June 22, 2026, which forces index funds to buy shares regardless of valuation — a structural source of demand independent of fundamentals
$ALAB vs $MRVL vs $CRDO: Full Financial Comparison
This is the core question for anyone researching Astera Labs stock: how does it actually compare to Marvell Technology and Credo Technology, the two names most often mentioned in the same breath?
Revenue Growth Comparison
| Company | Ticker | Quarterly Revenue | YoY Growth | QoQ Growth |
|---|---|---|---|---|
| Marvell Technology | $MRVL | $2.42 billion | +28% | +9% |
| Credo Technology | $CRDO | $437.0 million | +157% | +7.4% |
| Astera Labs | $ALAB | $308.4 million | +93% | +14% |
Credo is growing fastest off the smallest base. Marvell is the established giant, growing slowest in percentage terms but adding more absolute revenue than the other two combined. Astera Labs sits in between — sustaining nearly 100% annual growth at a $300M+ quarterly run rate.
Gross Margin Comparison
| Company | GAAP Gross Margin | Non-GAAP Gross Margin | Non-GAAP Operating Margin |
|---|---|---|---|
| Marvell Technology | 52.1% | 58.9% | 35% |
| Credo Technology | 68.2% | 68.3% | — |
| Astera Labs | 76.3% | 76.4% | 36.2% |
This table explains much of the ALAB stock premium. Astera’s gross margin runs about 24 points higher than Marvell’s and roughly 8 points higher than Credo’s — a function of its IP-dense connectivity silicon mix rather than higher-volume, lower-margin components.
Balance Sheet Comparison
| Company | Cash & Securities | Debt Position |
|---|---|---|
| Marvell Technology | — | $4.96B total debt, net debt/EBITDA 0.32x |
| Credo Technology | $1.4 billion | Net cash positive |
| Astera Labs | $1.2 billion | Net cash positive, total liabilities just $165M |
Both Astera Labs and Credo run debt-free balance sheets funded by operating cash flow — a real contrast to Marvell’s nearly $5 billion in debt (manageable at its scale, but a different capital structure).
Valuation Comparison: Is $ALAB Stock Overvalued?
| Company | NTM EV/EBITDA |
|---|---|
| Semiconductor sector average (24 companies) | ~31x |
| Marvell Technology | ~38.5x |
| Astera Labs | ~49x |
At roughly 49x forward EV/EBITDA, Astera Labs trades well above both Marvell and the broader semiconductor sector average. The market is pricing in years of Scorpio X execution going close to perfectly. Notably, Wall Street’s consensus 12-month price target sits around $245 — roughly 40% below where ALAB stock currently trades near $420, one of the widest gaps between analyst models and market price in large-cap semiconductors right now.
ALAB Stock Forecast: Bull Case vs. Bear Case
Bull case for Astera Labs stock: Best-in-class gross margin among direct peers, a debt-free balance sheet with $1B+ in cash, 93% revenue growth, and a new product line (Scorpio X) just beginning its ramp. Nasdaq-100 inclusion adds structural, valuation-insensitive demand. If AI infrastructure spending stays strong, Astera functions as a high-margin “toll booth” on that growth.
Bear case for Astera Labs stock: At ~49x forward EV/EBITDA, there’s little room for error. The Q2 margin guide already shows compression — and while management calls it a one-time accounting effect, further softness would likely be read as the start of margin normalization, a common pattern as high-margin semiconductor companies scale. The 60% drawdown from September 2025 to March 2026 is a reminder of how quickly sentiment can reverse on a richly valued AI stock.
Frequently Asked Questions About Astera Labs Stock
What is Astera Labs’ stock price today?
ALAB stock trades around $420 as of June 20, 2026, near its all-time high.
How much has Astera Labs stock grown in one year?
ALAB stock has risen roughly 3.5x over the past year, from about $120 to around $420, including a 60% drawdown and recovery along the way.
Is Astera Labs stock overvalued?
Astera Labs trades at roughly 49x forward EV/EBITDA, above the semiconductor sector average (~31x) and above peer Marvell (~38.5x). Wall Street’s consensus price target of about $245 is roughly 40% below the current price, suggesting many analysts view the stock as expensive relative to near-term fundamentals.
How does Astera Labs compare to Marvell and Credo?
Astera Labs is smaller than both by revenue but has the highest gross margin of the three (76.3% GAAP vs. 68.2% for Credo and 52.1% for Marvell). Credo is growing fastest by percentage; Marvell is the largest by absolute revenue.
Why did Astera Labs stock go up in 2026?
The main drivers are a 93% year-over-year revenue beat in Q1 FY26, the ramp of the Scorpio X-Series AI fabric switch, strong Q2 guidance, and confirmed Nasdaq-100 index inclusion effective June 22, 2026.
The Bottom Line on Astera Labs Stock
Going from $120 to $420 in a year is a rare outcome, and it’s backed by real financial improvement — not just multiple expansion. Revenue nearly doubled year-over-year, the company turned solidly profitable, and its margin profile leads its peer group.
But valuation has run well ahead of where it sat a year ago. The stock’s own price history is proof the market won’t hesitate to cut a richly valued AI name in half if growth or margins wobble — and with consensus analyst targets sitting roughly 40% below the current price, the gap between Wall Street’s models and market enthusiasm has rarely been wider. What happens next for Astera Labs stock depends almost entirely on whether the Scorpio X ramp lives up to the multiple already priced in.
This article is for informational purposes only and does not constitute financial or investment advice. Figures are based on company filings and public reporting as of June 20, 2026, and are subject to change with subsequent earnings reports.